Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

OssDsign

3.50 SEK-5.66 %18/9 17:29
Less than 1K followers

OSSD

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
-5.66 %
-16.67 %
-16.57 %
-43.09 %
-69.14 %
-76.51 %
-29.72 %
-60.89 %
-79.86 %

OssDsign is a developer and supplier of orthobiological products. The company develops and markets products that support the body's own healing ability, such as OssDsign Catalyst, which is a nanosynthetic bone graft for dual bone formation pathways through fusion mass. The company offers its products around the global market. OssDsign was founded in 2011 and is headquartered in Uppsala.

Read more
Market cap
387.19M SEK
Turnover
1.05M SEK
Revenue
180.16M
EBIT %
-25.95 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
3/11
2026

Interim report Q3'26

9/2
2027

Annual report '26

All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release2026-09-09 09:58

OssDsign AB: OssDsigns register PROPEL som utvärderar ryggradsfusioner med OssDsign Catalyst® omfattar nu fler än 400 patienter

OssDsign
Press release2026-08-31 20:11

DNB Carnegie Access: OssDsign: Highlights from DNB Carnegie Micro Cap Day

OssDsign
Third party research2026-08-19 06:55

OssDsign: Soft commercial momentum near-term - ABG

* Expected return to growth pushed out to Q4 * Adj. EBIT cut by 2.6%-3.6% for '26e-'28e * Fair value range revised down to SEK 3.8-6.2 (4.0-6.3) Small miss on sales, but lower opex in Q2 OssDsign reported mixed results in Q2: sales were 1% below expectations...

OssDsign

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2026-08-19 06:49

DNB Carnegie Access: OssDsign: Growth recovery remains elusive – Q2 review

OssDsign
Press release2026-08-18 08:14

DNB Carnegie Access: OssDsign: Q2 initial – Weak quarter as expected

OssDsign
Third party research2026-08-18 07:57

OssDsign: Beat on EBIT on lower sales - ABG

* 10% beat on adj EBIT but lower saIes * -16% organic growth (ABGSCe -15%) * No change in outlook, Q3 seasonally soft Q2 results OssDsign reported a mixed set of numbers in Q2 with 1% lower sales, lower gross margin, but good cost control on opex resulting...

OssDsign
Regulatory press release2026-08-18 07:00

OssDsign AB (publ) publishes Q2 2026 interim report

OssDsign
Regulatory press release2026-08-18 07:00

OssDsign AB (publ) publicerar delårsrapport för andra kvartalet 2026

OssDsign
Third party research2026-08-12 07:00

OssDsign: Waiting for the growth to return - ABG

* Sequentially flattish, but -15% organic drop in sales in Q2e * We assume a recovery in sales growth in H2'26e * Q2'26 results due 18 August Q2'26 expectations We expect sales development to have stabilised in Q2, at a similar level to Q1'26, but lower...

OssDsign
Press release2026-08-11 18:58

DNB Carnegie Access: OssDsign: We expect a sluggish Q2, eyeing H2 recovery – Q2 preview

OssDsign
Press release2026-06-25 17:30

OssDsign AB: OssDsign appoints Adam McCollister as new Vice President of Sales

OssDsign
Press release2026-06-25 17:30

OssDsign AB: OssDsign utser Adam McCollister till ny Vice President of Sales

OssDsign
Press release2026-06-10 10:55

Årsstämma har hållits i OssDsign AB

OssDsign
Press release2026-06-10 10:55

Annual General Meeting held in OssDsign AB

OssDsign
Press release2026-06-03 15:36

OssDsign AB: OssDsign Catalyst® överträffar tidigare generationers syntetiska bengraft som fristående behandling av trauma i preklinisk studie

OssDsign
Press release2026-06-03 10:21

OssDsign AB offentliggör uppdaterat förslag avseende styrelsearvode inför årsstämman 2026

OssDsign
Press release2026-06-03 10:21

OssDsign AB announces updated proposal regarding board fees ahead of the annual general meeting 2026

OssDsign
Press release2026-05-11 16:00

OssDsign AB: Kallelse till Årsstämma i OSSDSIGN AB

OssDsign
Press release2026-05-06 07:19

DNB Carnegie Access: OssDsign: Needs to prove slowdown is transitional – Q1 review

OssDsign
Third party research2026-05-05 13:50

OssDsign: Reset underway ahead of H2'26 - ABG

* Q1 in line with pre-announced numbers * Minor estimate revisions, H2'26 the key catalyst * Fair value range unchanged at SEK 4.0-6.2 Weak GM in Q1, opex offset Q1 sales confirmed the pre-announced number of SEK 36.9m (0% vs. ABGSCe) with an organic...

OssDsign